UT Health San Antonio infectious disease physicians are offering a podcast series called “COVID Minutes” for anyone who would like to learn more about the pandemic including health care workers, who can earn continuing medical education credits at no cost.
Being both on the frontlines and behind the scenes, the work done in the UT Health San Antonio pathology labs has been and continues to be crucial in the response to COVID-19 in the community. With 20,145 samples processed to date, the technologists in the pathology labs are “truly in the trenches” in the fight against COVID-19, said Marjorie David, MD, MS, director of the molecular diagnostic laboratory in the Department of Pathology and Laboratory Medicine.
The U.S. Food and Drug Administration announced Oct. 22 that the drug remdesivir (Veklury) is the first approved treatment for COVID-19. The antiviral medication has been tested in study sites internationally since February, including a study site led by UT Health San Antonio with its clinical partner, University Health System.
UT Health San Antonio was one of only four sites in Texas to receive the first doses of the Pfizer vaccine Dec. 14. The university received 5,850 doses, which gained emergency use authorization Dec. 10 from the U.S. Food and Drug Administration.